Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.15 EUR | +0.94% | +0.94% | +1.89% |
Apr. 02 | Bernstein starts AstraZeneca at 'outperform' | AN |
Feb. 22 | Transcript : Kerry Group plc Presents at 2024 Consumer Analyst Group of New York Conference, Feb-22-2024 10:00 AM |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.89% | 14.85B | A- | ||
-4.93% | 266B | A- | ||
-2.51% | 94.98B | C+ | ||
+3.19% | 46.39B | C+ | ||
+8.74% | 39.99B | B- | ||
-0.65% | 39.95B | B- | ||
-0.15% | 38.02B | B- | ||
-16.78% | 30.16B | B- | ||
-6.61% | 28.72B | A | ||
+11.32% | 24.54B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KRZ Stock
- Ratings Kerry Group plc